Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 8 for:    Ad26.COV2.S
Previous Study | Return to List | Next Study

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04765384
Recruitment Status : Not yet recruiting
First Posted : February 21, 2021
Last Update Posted : March 17, 2021
Sponsor:
Information provided by (Responsible Party):
Janssen Vaccines & Prevention B.V.

Brief Summary:
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S administered intramuscularly (IM) as a 2-dose schedule, in adult participants during the second and/or third trimester of pregnancy and (potentially) post-partum; to assess the humoral immune response in peripheral blood of adult participants, to Ad26.COV2.S administered IM as a 2-dose schedule during the second and/or third trimester of pregnancy, 28 days after the first and second vaccination.

Condition or disease Intervention/treatment Phase
Healthy Biological: Ad26.COV2.S Phase 2

Detailed Description:
There is an increased risk of severe coronavirus disease-2019 (COVID-19) during pregnancy, as well as an increased risk of adverse birth outcomes. Therefore, the aim of this study is to assess the safety, reactogenicity and immunogenicity of Ad26.COV2.S in adult participants in the second and/or third trimester of pregnancy. Ad26.COV2.S (also known as Ad26COVS1) is a monovalent vaccine composed of a recombinant, replication incompetent adenovirus type 26 (Ad26) vector, constructed to encode the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike (S) protein. For adult participants, the total study duration from screening until the last follow-up visit will be approximately 16 months (depending on the gestational age at enrollment and if the second dose of vaccine will need to be administered post-partum). The study will consist of a screening phase (28 days), vaccination phase (3 months) and a follow up phase (up to 12 months post-partum [PP]). For neonates/infants (born to adult participants who received vaccination) the total study duration from birth until the last follow-up visit will be approximately 12 months. Safety assessments will include immunogenicity assessments, physical examination, vital signs, clinical safety laboratory assessments, medical, obstetric and delivery history, neonate safety assessment, adverse events (AEs), serious adverse events (SAEs).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants
Estimated Study Start Date : March 12, 2021
Estimated Primary Completion Date : January 16, 2023
Estimated Study Completion Date : June 20, 2023

Arm Intervention/treatment
Experimental: Ad26.COV2.S
Participants will receive standard dose of Ad26.COV2.S as intramuscular injection (first dose on Day 1 and second dose on Day 57) based on safety and reactogenicity results assessed on Day 3 and 8 post dose 1. A low dose of Ad26.COV2.S may be administered if standard dose has safety and reactogenicity issues.
Biological: Ad26.COV2.S
Participants will receive IM injection of Ad26.COV2.S.
Other Name: JNJ-78436735, Ad26COVS1




Primary Outcome Measures :
  1. Number of Participants with Solicited Local Adverse Events (AEs) [ Time Frame: 7 days after each vaccination (Up to Day 64) ]
    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs are pre-defined local (at the injection site) AEs for which participants are specifically asked and which are noted by participants in their reactogenicity diary for 7 days post each vaccination. Solicited local AEs are: injection site pain/tenderness, erythema, swelling at the vaccination site.

  2. Number of Participants with Solicited Systemic AEs [ Time Frame: 7 days after each vaccination (Up to Day 64) ]
    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Participants will be instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events include fatigue, headache, nausea and myalgia.

  3. Number of Participants with Unsolicited AEs [ Time Frame: 28 days after each vaccination (Up to Day 85) ]
    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs are all AEs for which the participant is not specifically questioned in the participant's reactogenicity diary.

  4. Number of Participants with Serious Adverse Events (SAEs) [ Time Frame: Up to 2 years and 3 months ]
    SAE is any untoward medical occurrence that at any dose results in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

  5. Number of Participants with Medically-attended Adverse Events (MAAEs) [ Time Frame: 6 months after last vaccination (Up to Day 239) ]
    MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits will not be considered medically-attended visits. New onset of chronic diseases will be collected as part of the MAAEs.

  6. Number of Participants with MAAEs leading to Discontinuation [ Time Frame: Up to 2 years and 3 months ]
    MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits will not be considered medically-attended visits. New onset of chronic diseases will be collected as part of the MAAEs.

  7. Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination [ Time Frame: 28 days after first vaccination (Day 29) ]
    Serological response to vaccination as measured by enzyme-linked immunosorbent assay (S-ELISA, ELISA Units/milliliter [EU/mL]), 28 days after first vaccination will be reported.

  8. Number of Participants with Antibody Geometric Mean Concentration (GMC) 28 Days After First Vaccination [ Time Frame: 28 days after first vaccination (Day 29) ]
    Number of participants with antibody GMC (S-ELISA, EU/mL), 28 days after first vaccination will be reported.

  9. Serological Response to Vaccination as Measured by ELISA 28 Days After Second Vaccination [ Time Frame: 28 days after second vaccination (Day 85) ]
    Serological response to vaccination as measured by ELISA (S-ELISA, EU/mL), 28 days after second vaccination will be reported.

  10. Number of Participants with Antibody GMC 28 Days After Second Vaccination [ Time Frame: 28 days after second vaccination (Day 85) ]
    Number of participants with antibody GMC (S-ELISA, EU/mL), 28 days after second vaccination will be reported.


Secondary Outcome Measures :
  1. Number of Participants with Pregnancy Outcomes [ Time Frame: Up to 2 years and 3 months ]
    Number of participants with pregnancy outcomes (including, live term birth, live preterm birth, stillbirth, and abortion) will be reported.

  2. Number of Participants with Pregnancy Related AEs [ Time Frame: Up to 2 years and 3 months ]
    Number of participants with pregnancy-related AEs including: gestational diabetes, gestational hypertension, premature rupture of membranes, premature labor, premature uterine contractions, poor or restricted fetal growth, pre-eclampsia, eclampsia, vaginal or intrauterine hemorrhage (non-exhaustive) will be reported.

  3. Number of Neonates and Infants with any Complications, Anomalies and Deaths [ Time Frame: From birth up to 12 months ]
    Number of neonates and infants with any complication, anomalies and death will be reported. This will also includes normal neonate, term neonate with complications, preterm neonate with complications, neonatal infection, respiratory distress, congenital anomalies, neonatal death, low birth weight, and small for gestational age measured from birth up to 12 months of age (non exhaustive).

  4. Number of Neonates and Infants with SAEs [ Time Frame: From birth up to 12 months ]
    Number of neonates and infants (born to adult participants who received vaccination) with SAEs including multisystem inflammatory syndrome in children (MIS-C) from birth up to 12 months of age will be reported. Patients with MIS-C usually present with persistent fever, fatigue and a variety of signs and symptoms including multiorgan (example, cardiac, gastrointestinal, renal, hematologic, dermatologic, neurologic) involvement, elevated inflammatory markers and, in severe cases, hypotension and shock.

  5. Number of Neonates and Infants with MAAEs [ Time Frame: From birth up to 6 months ]
    Number of neonates and infants (born to adult participants who received vaccination) with MAAEs from birth up to 6 months of age will be reported.

  6. Number of Neonates and Infants with MAAEs leading to Study Discontinuation [ Time Frame: From birth up to 12 months ]
    Number of neonates and infants (born to adult participants who received vaccination) with MAAEs leading to discontinuation from birth up to 12 months of age will be reported.

  7. Serological Response to Vaccination as Measured by ELISA [ Time Frame: From birth up to 2 months, 6 months, 12 months ]
    Serological response to vaccination as measured by ELISA (S-ELISA, EU/mL) will be reported for neonates and infants (born to adult participants who received vaccination) at birth and up to 2 months, 6 months, and 12 months of age.

  8. Number of Neonates and Infants with Antibody GMC [ Time Frame: From birth up to 2 months, 6 months, 12 months ]
    Number of neonates and infants (born to adult participants who received vaccination) with antibody GMC (S-ELISA, EU/mL) will be reported at birth and up to 2 months, 6 months, and 12 months of age.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • If on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study
  • Participant will be included on the basis of physical examination, medical history, and vital signs
  • Participant will be at second or third trimester of pregnancy, that is, Week 16 to Week 38 of gestation(inclusive), at the time of vaccination, based on ultrasound at the time of screening (unless performed elsewhere within 28-days prior to vaccination)
  • Participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine
  • Participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study

Exclusion Criteria:

  • Participants with medical or obstetric histories that put them at higher risk for maternal or fetal complications (example, preeclampsia, premature birth during previous pregnancy)
  • Participant with abnormal pregnancy screening test (example, ultrasound fetal abnormalities, maternal blood screen)
  • Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence
  • Participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)
  • Participant has a history of any serious, chronic, or progressive neurological disorders or seizures including Guillain-Barre syndrome, with the exception of febrile seizures during childhood
  • Participant has a positive diagnostic test result for past (serological testing) or current (polymerase chain reaction [PCR] based viral ribonucleic acid [RNA] detection) severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection at screening or Day 1 (if more than 4 days in between)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04765384


Contacts
Layout table for location contacts
Contact: Study Contact 844-434-4210 JNJ.CT@sylogent.com

Locations
Show Show 62 study locations
Sponsors and Collaborators
Janssen Vaccines & Prevention B.V.
Investigators
Layout table for investigator information
Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial Janssen Vaccines & Prevention B.V.
Layout table for additonal information
Responsible Party: Janssen Vaccines & Prevention B.V.
ClinicalTrials.gov Identifier: NCT04765384    
Other Study ID Numbers: CR108962
2020-005330-14 ( EudraCT Number )
VAC31518COV2004 ( Other Identifier: Janssen Vaccines & Prevention B.V. )
First Posted: February 21, 2021    Key Record Dates
Last Update Posted: March 17, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
URL: https://www.janssen.com/clinical-trials/transparency

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No